B
UTHR icon

Baird’s United Therapeutics UTHR Stock Holding History

Baird’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$2.16M Sell
12,542
-14,390
-53% -$2.19M 0.02% 532
2014
Q4 		$3.49M Sell
26,932
-3,850
-13% -$496K 0.04% 420
2014
Q3 		$3.96M Sell
30,782
-1,570
-5% -$162K 0.06% 296
2014
Q2 		$2.86M Buy
32,352
+2,830
+10% +$272K 0.04% 389
2014
Q1 		$2.78M Buy
29,522
+255
+0.9% +$26.1K 0.04% 397
2013
Q4 		$3.31M Buy
29,267
+18,727
+178% +$1.69M 0.06% 360
2013
Q3 		$831K Buy
+10,540
New +$770K 0.02% 637

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Baird's UTHR Position: Q1 2015 in Review

Baird reduced its United Therapeutics (UTHR) stake by 53% in Q1 2015, selling an estimated $2.19M and leaving 12,542 shares worth $2.16M. The position accounts for 0.02% of the portfolio, ranked #532.

Baird first reported a position in UTHR in Q3 2013 and has held it in 7 quarters since. The position peaked at $3.96M in Q3 2014. 366 funds tracked by Wall St. Rank hold UTHR as of Q1 2015.

  • Baird held 12,542 shares of United Therapeutics worth $2.16M as of Q1 2015.
  • Baird sold 14,390 United Therapeutics shares in Q1 2015, an estimated $2.19M.
  • United Therapeutics made up 0.02% of Baird's portfolio in Q1 2015, its #532 holding.
  • Baird first reported a position in United Therapeutics in Q3 2013 and has held it in 7 quarters since.
  • Baird's United Therapeutics position peaked at $3.96M in Q3 2014.
  • 366 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.